Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

CEFALOTIN FOR IMPURITY B IDENTIFICATION CRS (10 MG)

CEFALOTIN FOR IMPURITY B IDENTIFICATION CRS (10 MG)

58-71-9

DISCOVER
CEFOTAXIME FOR PEAK IDENTIFICATION CRS (10 MG)

CEFOTAXIME FOR PEAK IDENTIFICATION CRS (10 MG)

64485-93-4

DISCOVER
CHLORPROMAZINE IMPURITY A CRS(15 MG)

CHLORPROMAZINE IMPURITY A CRS(15 MG)

NA

DISCOVER
CHLORPROMAZINE IMPURITY E CRS(10 MG)

CHLORPROMAZINE IMPURITY E CRS(10 MG)

92-39-7

DISCOVER
DESOGESTREL CRS (60 MG)

DESOGESTREL CRS (60 MG)

54024-22-5

DISCOVER
DESOGESTREL FOR SYSTEM SUITABILITY CRS (10 MG)

DESOGESTREL FOR SYSTEM SUITABILITY CRS (10 MG)

54024-22-5

DISCOVER
DEXAMETHASONE ISONICOTINATE FOR IMPURITY C IDENTIFICATION CR

DEXAMETHASONE ISONICOTINATE FOR IMPURITY C IDENTIFICATION CR

2265-64-7

DISCOVER
EMEDASTINE IMPURITY E CRS (10MG)

EMEDASTINE IMPURITY E CRS (10MG)

NA

DISCOVER
GEMFIBROZIL CRS (5 MG)

GEMFIBROZIL CRS (5 MG)

25812-30-0

DISCOVER
GEMFIBROZIL FOR SYSTEM SUITABILITY CRS (0.196 MG)

GEMFIBROZIL FOR SYSTEM SUITABILITY CRS (0.196 MG)

25812-30-0

DISCOVER
GLIMEPIRIDE CRS (110 MG)

GLIMEPIRIDE CRS (110 MG)

93479-97-1

DISCOVER
GLIMEPIRIDE FOR SYSTEM SUITABILITY CRS (0.012 MG)

GLIMEPIRIDE FOR SYSTEM SUITABILITY CRS (0.012 MG)

93479-97-1

DISCOVER